Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Ventyx Biosciences announces positive topline results from Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors INTRATOMICS and UK’s Paragraf sign MoU to pioneer next-generation Graphene-Based Sensor Technologies PlanetiQ wins $24.3M NOAA contract, largest commercial satellite weather data award ever Paragraf closes $55M Series C funding round Ferric launches new Integrated Voltage Regulator for AI and high-performance processors VORAGO introduces VA5 family of Dual-Core Rad-Hard and Rad-Tolerant Microcontrollers for next-gen space and defense systems
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Website powered by 100% renewable energy Privacy Policy